A randomized, double-blind, double-dummy, active-controlled, parallel group study of a single dose of ACZ885 [canakinumab] in hospitalized patients with acute gout.
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2013
At a glance
- Drugs Canakinumab (Primary) ; Dexamethasone
- Indications Gouty arthritis
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 15 Mar 2012 Actual end date 23 Oct 2009 added as reported by EudraCT.
- 03 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.